Healthcare provider profile · identity verified

James Patrick Seneca, NP

Nurse Practitioner · NEW IBERIA, LA · NPI 1750510152

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Tradjenta	Linagliptin	354	25
Gabapentin	Gabapentin	257	36
Potassium Chloride	Potassium Chloride	240	34
Amlodipine Besylate	Amlodipine Besylate	231	23
Trazodone Hcl	Trazodone Hcl	190	25
Pantoprazole Sodium	Pantoprazole Sodium	182	30
Alprazolam	Alprazolam	174	28
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	166	58
Levothyroxine Sodium	Levothyroxine Sodium	144	18
Quetiapine Fumarate	Quetiapine Fumarate	136	23
Clonazepam	Clonazepam	129	18
Lisinopril	Lisinopril	122	16
Tramadol Hcl	Tramadol Hcl	111	31
Atorvastatin Calcium	Atorvastatin Calcium	100	14
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	97	37
Dexamethasone	Dexamethasone	92	29
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	90	20
Metformin Hcl	Metformin Hcl	90	suppressed
Baclofen	Baclofen	73	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	72	suppressed
Metoprolol Succinate	Metoprolol Succinate	72	suppressed
Glimepiride	Glimepiride	70	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	70	suppressed
Eliquis	Apixaban	68	11
Furosemide	Furosemide	66	16
Tamsulosin Hcl	Tamsulosin Hcl	65	suppressed
Myrbetriq	Mirabegron	63	suppressed
Duloxetine Hcl	Duloxetine Hcl	61	suppressed
Buspirone Hcl	Buspirone Hcl	59	18
Jardiance	Empagliflozin	58	suppressed
Citalopram Hbr	Citalopram Hydrobromide	53	suppressed
Donepezil Hcl	Donepezil Hcl	53	suppressed
Carvedilol	Carvedilol	52	11
Sucralfate	Sucralfate	52	suppressed
Divalproex Sodium	Divalproex Sodium	50	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	49	38
Losartan Potassium	Losartan Potassium	48	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	48	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	44	13
Azithromycin	Azithromycin	42	35
Fluticasone Propionate	Fluticasone Propionate	42	suppressed
Lorazepam	Lorazepam	42	14
Clopidogrel	Clopidogrel Bisulfate	41	suppressed
Sertraline Hcl	Sertraline Hcl	41	suppressed
Pregabalin	Pregabalin	39	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	39	suppressed
Memantine Hcl	Memantine Hcl	38	suppressed
Novolin R Flexpen	Insulin Regular, Human	35	suppressed
Prednisone	Prednisone	35	11
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	35	20
Amitriptyline Hcl	Amitriptyline Hcl	33	suppressed
Mirtazapine	Mirtazapine	31	suppressed
Pravastatin Sodium	Pravastatin Sodium	30	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	29	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	29	suppressed
Spironolactone	Spironolactone	29	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	28	suppressed
Omeprazole	Omeprazole	28	suppressed
Risperidone	Risperidone	28	suppressed
Novolin R	Insulin Regular, Human	27	suppressed
Latanoprost	Latanoprost	26	suppressed
Metformin Hcl Er	Metformin Hcl	26	suppressed
Temazepam	Temazepam	26	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	25	20
Xarelto	Rivaroxaban	25	suppressed
Fentanyl	Fentanyl	24	suppressed
Meloxicam	Meloxicam	24	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	23	suppressed
Farxiga	Dapagliflozin Propanediol	22	suppressed
Humulin R	Insulin Regular, Human	22	suppressed
Ondansetron Hcl	Ondansetron Hcl	22	14
Phenobarbital	Phenobarbital	22	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Glipizide	Glipizide	20	suppressed
Primidone	Primidone	20	suppressed
Budesonide Dr	Budesonide	19	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	19	suppressed
Fluconazole	Fluconazole	19	14
Lantus	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Nystatin	Nystatin	19	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	18	16
Diltiazem Hcl	Diltiazem Hcl	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	18	suppressed
Simvastatin	Simvastatin	18	suppressed
Enalapril Maleate	Enalapril Maleate	17	suppressed
Labetalol Hcl	Labetalol Hcl	17	suppressed
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	17	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	17	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	16	16
Levetiracetam	Levetiracetam	16	suppressed
Diazepam	Diazepam	15	suppressed
Valsartan	Valsartan	15	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	14	suppressed
Cyproheptadine Hcl	Cyproheptadine Hcl	14	suppressed
Entresto	Sacubitril/Valsartan	14	suppressed
Finasteride	Finasteride	14	suppressed
Mupirocin	Mupirocin	14	suppressed
Scopolamine	Scopolamine	14	suppressed
Bumetanide	Bumetanide	13	suppressed
Clobetasol Propionate	Clobetasol Propionate	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	12	suppressed
Clindamycin Hcl	Clindamycin Hcl	12	11
Ceftriaxone	Ceftriaxone Sodium	11	suppressed
Clonidine	Clonidine	11	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Divalproex Sodium Er	Divalproex Sodium	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Moxifloxacin	Moxifloxacin Hcl	11	suppressed
Timolol Maleate	Timolol Maleate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error